NCT07002047

Real World and Epidemiology Study of Medically Attended Chlamydia Trachomatis Among Adults in Germany

• Status: Active Not Recruiting
• Phase: —
• Study type: Observational
• Enrollment: 81,239 (actual)
• Sponsor: Sanofi · Industry
• Sex: All
• Age: 14 Years – 44 Years
• Healthy volunteers: Not accepted

Summary

This study assesses the epidemiologic situation of chlamydia trachomatis, its complications and long term sequalae and related healthcare resource utilization and costs among adults in Germany. The study is a retrospective cohort study based on German Statutory Health Insurance (SHI) claims data for adolescents and adults aged 14 to 44 years in the years 2008-2022 with documented (confirmed) diagnosis of CT. Study Objectives are to: 1. Estimate frequency of potential short-term complications and long-term sequelae in patients with medically attended chlamydia infection 2. Analyze time from first documented prevalent CT infection to first potential complication/sequelae diagnosis 3. Estimate frequency of re-infection (chlamydia recurrence) and co-infections with other sexually transmitted infections (STIs) in patients with medically-attended chlamydia infection 4. Estimate absolute healthcare resource utilization (by level of care and specialty) and costs in patients with chlamydia infection, including for potential short-term complications and long-term sequelae 5. Estimate administrative prevalence of medically-attended chlamydia infection in the overall study population 6. Estimate administrative prevalence of diagnoses potentially associated with a chlamydia infection (i.e., short-term complications/long-term sequelae) in the overall study population 7. Estimate frequency of chlamydia testing in the overall study population

Conditions

• Chlamydia Trachomatis

Timeline

• Start date: 2025-03-13
• Primary completion: 2026-02-17
• Completion: 2026-02-17
• First posted: 2025-06-03
• Last updated: 2025-06-03

Locations

1 site across 1 country: Germany